ClinicalTrials.Veeva

Menu

Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)

N

Nanjing Medical University

Status

Not yet enrolling

Conditions

Hepatitis D
RNA Virus Infections
Antibodies; Anti-D
Hepatitis B

Treatments

Diagnostic Test: HDV-Ab (IgG), HDV-RNA, RNA genotype

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT05394623
2021-8764

Details and patient eligibility

About

In China, there is no recommendation for Hepatitis D virus (HDV) screening, but the fact is estimated that one-third of the world's population of individuals with chronic Hepatitis B virus (HBV) infection live in China while we do not know the prevalence of co-infection of HBV/HDV in China. So far, no nationwide study has been undertaken to evaluate the epidemiology of hepatitis D, on the other hand, reports of HDV infection rate in different regions of China are not consistent because of the different detection methods and detection objects. Here, we plan to test HDV-Ab/RNA for 5000 HBsAg reactive samples from 10 major tertiary hospital and to know the prevalence and disease burden of HDV in China.

Enrollment

5,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Positive HBV surface antigen (HBsAg)
  2. Age 18 yeas and above

Exclusion criteria

  1. Severe cardiac, renal, respiratory, hematological, or psychiatric illness.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems